A Phase 3 interventional study of Pelacarsen and Placebo in Acute Coronary Syndrome (ACS), sponsored by Novartis Pharmaceuticals. Withdrawn. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Acute Coronary Syndrome by Novartis — 2 open to participants now, 2 under way, 1 of them phase 3. Acute Coronary Syndrome · Novartis.
Among the 11 studies in Acute Coronary Syndrome by Novartis, this one is the 11th largest by enrollment, is one of 2 that started in 2026, is one of 8 in phase 3, and was the 10th registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.
Browse Acute Coronary Syndrome studies →2 of the 11 studies in Acute Coronary Syndrome by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Argentina, Australia, Canada and 11 more countries
Ages 18+
Novartis Pharmaceuticals
Ages 18–100
By country, each count listing its studies:
Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 8 · Phase 4 1
First in 2003; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 400 across the 11 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
1 of the studies in Acute Coronary Syndrome by Novartis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07102628Phase 3Novartis PharmaceuticalsEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | 2027-02-11 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Acute Coronary Syndrome by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
CTQJ230A1US13 is a randomized, double-blind, placebo-controlled, multicenter phase IIIb study designed to evaluate the efficacy, safety, tolerability, and coronary plaque effects of early pelacarsen (TQJ230) initiation in participants with elevated Lp(a) and recent acute coronary syndrome (ACS).
This study consists of Lp(a) measurement and additional screening assessments, a double-blind treatment period of 18 months, and a 16-week safety follow up period from the last dose. Efficacy, safety, and tolerability of pelacarsen (TQJ230) compared to placebo will be assessed throughout the study, with primary analysis at Day 180 and final analysis at Day 540.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pelacarsen (TQJ230) 80 mg s.c. QM
Drug: Pelacarsen
Corresponding placebo s.c. QM
Drug: Placebo
Pelacarsen 80 mg subcutaneously (s.c.) once a month (QM)
Also known as: TQJ230
Placebo subcutaneously (s.c.) once a month (QM)
Change in log-transformed Lp(a) concentration
Change in log-transformed Lipoprotein A (Lp(a)) concentration from baseline to Day 180
Time frame: Baseline, Day 180
Proportion of participants with Lp(a) < 105 nmol/L
Proportion of participants with Lipoprotein A (Lp(a)) \< 105 nmol/L
Time frame: Day 180 and Day 540
Proportion of participants with TEAEs, TESAEs,TEAEs or TESAEs leading to study drug discontinuation and TEAEs of special interest
Proportion of participants with: * Treatment-emergent adverse events (TEAEs) * Treatment-emergent serious adverse events (TESAEs) * TEAEs or TESAEs leading to study drug discontinuation * TEAEs of special interest
Time frame: 22 months
Summary of observed values for Glomerular Filtration Rate (GFR)
Summary of observed values in GFR (Safety laboratory parameters)
Time frame: Up to 18 months
Change from baseline in Glomerular Filtration Rate (GFR)
Change from baseline in GFR (Safety laboratory parameters)
Time frame: Baseline and up to 18 months
Summary of observed values for Heart Rate (HR)
Summary of observed values for HR (electrocardiogram)
Time frame: Up to 18 months
Change from baseline in Heart Rate (HR)
Change from baseline in HR (electrocardiogram)
Time frame: Baseline and up to 18 months
Summary of observed values for Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Summary of observed values for SBP and DBP (vital signs)
Time frame: Up to 18 months
Change from baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Change from baseline in SBP and DBP (vital signs)
Time frame: Baseline and up to 18 months
Change from baseline to Day 540 in non-calcified coronary plaque volume
Change from baseline to Day 540 in non-calcified coronary plaque volume, as assessed by CCTA
Time frame: Baseline and Day 540
No study locations are listed for this record.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Jan 2029, 28 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: start Aug 2026 → Sep 2026, primary completion Dec 2028 → Jan 2029 and completion Dec 2028 → Jan 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint
Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pelacarsen